B. Riley reaffirmed their buy rating on shares of Arbutus Biopharma (NASDAQ:ABUS) in a research note issued to investors on Monday, TipRanks reports. The firm currently has a $6.00 target price on the biopharmaceutical company’s stock.

A number of other equities research analysts have also issued reports on ABUS. Robert W. Baird lowered their target price on Arbutus Biopharma from $8.00 to $4.00 and set an outperform rating for the company in a research note on Friday, March 27th. Zacks Investment Research raised Arbutus Biopharma from a hold rating to a buy rating and set a $1.25 price target for the company in a report on Tuesday, May 5th. ValuEngine raised Arbutus Biopharma from a hold rating to a buy